Your session is about to expire
← Back to Search
Cancer Vaccine
HPV Vaccination Strategies for Cervical Cancer Prevention (IVaccinate Trial)
N/A
Recruiting
Led By Electra D Paskett
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights
IVaccinate Trial Summary
This trial is testing a new way to get people to get the HPV vaccine in four states in America. The HPV vaccine can help prevent cervical cancer.
Who is the study for?
This trial is for healthcare providers and office staff in certain Appalachian states who care for patients aged 11-26, provide immunizations, and are involved in the vaccine process. Participants must be able to speak, read, and write English.Check my eligibility
What is being tested?
The study tests if using educational materials, promotional efforts, and electronic health record reminders can increase HPV vaccination rates among children and young adults within four Appalachian state health systems.See study design
What are the potential side effects?
Since this trial focuses on improving vaccination rates through interventions like education rather than testing a new drug or vaccine itself, it does not directly involve medical side effects.
IVaccinate Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 60 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in attitudes of providers
Change in knowledge of providers
Change in rate of HPV vaccination initiation among those 13-26
+3 moreIVaccinate Trial Design
2Treatment groups
Experimental Treatment
Group I: ARM II (DELAYED INTERVENTION)(education, reminder, usual care)Experimental Treatment4 Interventions
Health systems, providers, and patients receive usual care for 12 months, then receive multi-level intervention as in Arm I.
Group II: ARM I (EARLY INTERVENTION) (educational material, reminders)Experimental Treatment4 Interventions
Health systems receive educational materials consisting of posters, brochures and handouts. Providers complete survey about HPV knowledge, participate in educational session over 1 hour and receive educational handouts on the HPV vaccine. Patients receive educational materials about HPV vaccine and reminder letters for HPV vaccination
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,932,167 Total Patients Enrolled
Ohio State University Comprehensive Cancer CenterLead Sponsor
320 Previous Clinical Trials
288,667 Total Patients Enrolled
Electra D PaskettPrincipal InvestigatorOhio State University Comprehensive Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- The trial does not include healthcare providers, such as doctors, nurses, and office staff.People who work with the vaccine at the clinic.You are able to communicate in English through speaking, reading, and writing.You live in one of the areas that are included in this program.You must be able to understand and communicate in English as there are not many Spanish speakers in the study area.I provide care to patients aged 11-26.I am up to date with my vaccinations.You receive medical care from one of the participating healthcare organizations.I'm sorry, it seems like there's not enough information to rewrite this criterion. Can you please provide more context or details?
Research Study Groups:
This trial has the following groups:- Group 1: ARM I (EARLY INTERVENTION) (educational material, reminders)
- Group 2: ARM II (DELAYED INTERVENTION)(education, reminder, usual care)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still opportunities for volunteers to join this clinical experiment?
"Indeed, according to the information on clinicaltrials.gov, this trial is actively seeking participants and has been doing so since October 21st 2020. The study aims to recruit 1500 individuals across 3 different sites before its completion date of April 18th 2022."
Answered by AI
How many individuals have been enlisted for this clinical trial?
"This trial necessitates 1500 participants with the specified inclusion criteria. Those who would like to take part can do so at University of Kentucky/Markey Cancer Center in Lexington, KY or University of Virginia in Charlottesville, VA."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger